Par, Ortho-McNeil Settle Ultracet Patent Spat

Law360, New York (July 19, 2007, 12:00 AM EDT) -- Generic drug maker Par Pharmaceuticals has admitted to infringing a patent covering the acute pain treatment Ultracet as part of a deal to resolve litigation brought by Johnson & Johnson subsidiary Ortho-McNeil Inc.

Par conceded that the reissue patent for Ultracet is valid and enforceable, and that Par infringed that patent by selling generic Ultracet in the U.S., according to a statement put out by Ortho-McNeil. Woodcliff lake, N.J.-based Par will pay Ortho-McNeil a lump sum to cover past damages, as well as a royalty on...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.